Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea G Cochran

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Journal of Molecular Biology|July 25, 2006
Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antibody agonistsBing Li, Stephen J Russell, Deanne M Compaan, et al.
Nature Communications|October 13, 2017
Non-canonical reader modules of BAZ1A promote recovery from DNA damageMariano Oppikofer, Meredith Sagolla, Benjamin Haley, et al.
Biochemistry|May 21, 2003
BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding siteNathaniel C Gordon, Borlan Pan, Sarah G Hymowitz, et al.
Immunity|October 22, 2002
BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2Nobuhiko Kayagaki, Minhong Yan, Dhaya Seshasayee, et al.
Nature Structural & Molecular Biology|January 17, 2012
Phosphorylation-dependent activity of the deubiquitinase DUBAOscar W Huang, Xiaolei Ma, JianPing Yin, et al.
Structure (London, England : 1993)|September 28, 2011
Wnt antagonists bind through a short peptide to the first β-propeller domain of LRP5/6Eric Bourhis, Weiru Wang, Christine Tam, et al.
Journal of Medicinal Chemistry|May 1, 2009
A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora BIgnacio Aliagas-Martin, Dan Burdick, Laura Corson, et al.
Nature|December 4, 2014
Deubiquitinase DUBA is a post-translational brake on interleukin-17 production in T cellsSascha Rutz, Nobuhiko Kayagaki, Qui T Phung, et al.
Bioorganic & Medicinal Chemistry Letters|June 14, 2017
Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistanceTerry D Crawford, Steffan Vartanian, Alexandre Côté, et al.
Journal of Medicinal Chemistry|July 18, 2008
A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailabilityThomas E Rawson, Matthias Rüth, Elizabeth Blackwood, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Journal of Molecular Biology|July 25, 2006
Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antibody agonistsBing Li, Stephen J Russell, Deanne M Compaan, et al.
Nature Communications|October 13, 2017
Non-canonical reader modules of BAZ1A promote recovery from DNA damageMariano Oppikofer, Meredith Sagolla, Benjamin Haley, et al.
Biochemistry|May 21, 2003
BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding siteNathaniel C Gordon, Borlan Pan, Sarah G Hymowitz, et al.
Immunity|October 22, 2002
BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2Nobuhiko Kayagaki, Minhong Yan, Dhaya Seshasayee, et al.
Nature Structural & Molecular Biology|January 17, 2012
Phosphorylation-dependent activity of the deubiquitinase DUBAOscar W Huang, Xiaolei Ma, JianPing Yin, et al.
Structure (London, England : 1993)|September 28, 2011
Wnt antagonists bind through a short peptide to the first β-propeller domain of LRP5/6Eric Bourhis, Weiru Wang, Christine Tam, et al.
Journal of Medicinal Chemistry|May 1, 2009
A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora BIgnacio Aliagas-Martin, Dan Burdick, Laura Corson, et al.
Nature|December 4, 2014
Deubiquitinase DUBA is a post-translational brake on interleukin-17 production in T cellsSascha Rutz, Nobuhiko Kayagaki, Qui T Phung, et al.
Bioorganic & Medicinal Chemistry Letters|June 14, 2017
Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistanceTerry D Crawford, Steffan Vartanian, Alexandre Côté, et al.
Journal of Medicinal Chemistry|July 18, 2008
A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailabilityThomas E Rawson, Matthias Rüth, Elizabeth Blackwood, et al.
Pageof 4